1. AEG Tumors
a. in metastastic disease - MSI-H/d-MMR (ICI), Her2+/neu (Trastuzumab), PDL-1 CPS/TAP (ICI), Claudin 18.2 (Zolbetuximab)
b. in Stadium IB-III, off-label use possible - Her2+/neu, PD1-PDL-1 CPS/TAP
No comments:
Post a Comment